{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mediastinal+Lymphomas&page=3",
    "query": {
      "condition": "Mediastinal Lymphomas",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 120,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mediastinal+Lymphomas&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mediastinal+Lymphomas&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T12:11:06.597Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02652715",
      "title": "Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Adult T-Cell Leukemia/Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "B Lymphoblastic Leukemia/Lymphoma",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Burkitt Leukemia",
        "Central Nervous System Lymphoma",
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3 Follicular Lymphoma",
        "Hepatosplenic T-Cell Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle Cell Lymphoma",
        "Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Mycosis Fungoides",
        "Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Nodal Marginal Zone Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Post-Transplant Lymphoproliferative Disorder",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Primary Effusion Lymphoma",
        "Sezary Syndrome",
        "Splenic Marginal Zone Lymphoma",
        "Subcutaneous Panniculitis-Like T-Cell Lymphoma",
        "Systemic Anaplastic Large Cell Lymphoma",
        "T Lymphoblastic Leukemia/Lymphoma",
        "Transformed Recurrent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Salvia hispanica Seed",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-01-19",
      "completion_date": "2019-11-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652715"
    },
    {
      "nct_id": "NCT06784726",
      "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent Grade 3b Follicular Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent Primary Mediastinal Large B-Cell Lymphoma",
        "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory Grade 3b Follicular Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Primary Mediastinal Large B-Cell Lymphoma",
        "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-09-04",
      "completion_date": "2033-04-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06784726"
    },
    {
      "nct_id": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3a Follicular Lymphoma",
        "Mediastinal Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Waldenstrom Macroglobulinemia",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Kami Maddocks",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-01-12",
      "completion_date": "2019-01-03",
      "has_results": false,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02950220"
    },
    {
      "nct_id": "NCT03749018",
      "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aggressive Non-Hodgkin Lymphoma",
        "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma",
        "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma",
        "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Indolent Non-Hodgkin Lymphoma",
        "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma",
        "Transformed Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "David Bond, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2019-01-02",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03749018"
    },
    {
      "nct_id": "NCT05826535",
      "title": "Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rondecabtagene autoleucel (ronde-cel)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2023-05-09",
      "completion_date": "2031-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 32,
      "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 27 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05826535"
    },
    {
      "nct_id": "NCT02623920",
      "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Mediastinal Large B-cell Lymphoma",
        "Grey Zone Lymphoma",
        "High Grade B Cell Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-12-16",
      "completion_date": "2017-05-17",
      "has_results": false,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02623920"
    },
    {
      "nct_id": "NCT06533579",
      "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "Large B-cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Marginal Zone Lymphoma",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Burkitt Lymphoma",
        "Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
        "Non Hodgkin Lymphoma",
        "Mixed Phenotype Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Dose Level 1, VNX-101",
          "type": "GENETIC"
        },
        {
          "name": "Dose Level 2, VNX-101",
          "type": "GENETIC"
        },
        {
          "name": "Dose Level 3, VNX-101",
          "type": "GENETIC"
        },
        {
          "name": "Dose Level 4, VNX-101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Vironexis Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "13 Years to 90 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-05-30",
      "completion_date": "2031-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533579"
    },
    {
      "nct_id": "NCT00532259",
      "title": "CT-011 MAb in DLBCL Patients Following ASCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Large Cell, Diffuse",
        "Lymphoma, Mixed Cell, Diffuse",
        "Primary Mediastinal Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "CT-011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CureTech Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2007-10",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-09-12",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • San Diego, California • Atlanta, Georgia + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00532259"
    },
    {
      "nct_id": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Burkitt Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Grade 3a Follicular Lymphoma",
        "Recurrent Grade 3b Follicular Lymphoma",
        "Recurrent Gray-Zone Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mediastinal Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Grade 1 Follicular Lymphoma",
        "Refractory Grade 2 Follicular Lymphoma",
        "Refractory Grade 3 Follicular Lymphoma",
        "Refractory Grade 3a Follicular Lymphoma",
        "Refractory Gray-Zone Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Marginal Zone Lymphoma",
        "Refractory Mediastinal Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2016-11-15",
      "completion_date": "2025-11-24",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02568553"
    },
    {
      "nct_id": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Ann Arbor Stage III Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage III Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage III Marginal Zone Lymphoma",
        "Ann Arbor Stage IV Grade 1 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage IV Marginal Zone Lymphoma",
        "Composite Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Grade 3b Follicular Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Marginal Zone Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Richter Syndrome"
      ],
      "interventions": [
        {
          "name": "CD47 Antagonist ALX148",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2021-10-13",
      "completion_date": "2028-03-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-19T12:11:06.597Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025800"
    }
  ]
}